RUNX2 Antibody - #AF5186

>>买2送1 进行中>>
>>赠JD卡 进行中>>
(97)   (48)  
产品: RUNX2 抗体
货号: AF5186
描述: Rabbit polyclonal antibody to RUNX2
应用: WB IHC IF/ICC
文献验证: WB, IHC, IF/ICC
反应: Human, Mouse, Rat
预测: Pig, Bovine, Horse, Sheep, Rabbit, Chicken, Xenopus
蛋白号: Q13950
RRID: AB_2837672

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1250 现货
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售
相关下载
MS Report
HPLC Report
MSDS
说明书
COA
实验方案
WB Handbook
IHC Protocol
IF/ICC Protocol

产品描述

来源:
Rabbit
应用:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse, Rat
克隆:
Polyclonal
特异性:
RUNX2 Antibody detects endogenous levels of total RUNX2.
RRID:
AB_2837672
引用格式: Affinity Biosciences Cat# AF5186, RRID:AB_2837672.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

Acute myeloid leukemia 3 protein; Alpha subunit 1; AML3; CBF alpha 1; CBF-alpha-1; CBFA1; CCD; CCD1; Cleidocranial dysplasia 1; Core binding factor; Core binding factor runt domain alpha subunit 1; Core binding factor subunit alpha 1; Core-binding factor subunit alpha-1; MGC120022; MGC120023; Oncogene AML 3; Oncogene AML-3; OSF 2; OSF-2; OSF2; Osteoblast specific transcription factor 2; Osteoblast-specific transcription factor 2; OTTHUMP00000016533; PEA2 alpha A; PEA2-alpha A; PEA2aA; PEBP2 alpha A; PEBP2-alpha A; PEBP2A1; PEBP2A2; PEBP2aA; PEBP2aA1; Polyomavirus enhancer binding protein 2 alpha A subunit; Polyomavirus enhancer-binding protein 2 alpha A subunit; Runt domain; Runt related transcription factor 2; Runt-related transcription factor 2; RUNX2; RUNX2_HUMAN; SL3 3 enhancer factor 1 alpha A subunit; SL3-3 enhancer factor 1 alpha A subunit; SL3/AKV core binding factor alpha A subunit; SL3/AKV core-binding factor alpha A subunit;

抗原和靶标

免疫原:

A synthesized peptide derived from human RUNX2, corresponding to a region within the internal amino acids.

基因/基因ID:
RUNX2(860)
描述:
Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis. Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters.

研究领域

· Human Diseases > Cancers: Overview > Transcriptional misregulation in cancer.

文献引用

1). Gut microbial alterations in arginine metabolism determine bone mechanical adaptation. Cell metabolism, 2024 (PubMed: 38718794) [IF=27.7]
2). Osteoblastic and anti-osteoclastic activities of strontium-substituted silicocarnotite ceramics: In vitro and in vivo studies. Bioactive Materials, 2020 (PubMed: 32280833) [IF=18.9]

Application: WB    Species: Mice    Sample: bone and osteoid tissues

Fig. 4 (A) Expression of the osteogenesis-specific genes including RUNX2, BSP, OPN and OCN; (B) Western blotting showed that Sr-CPS affected the Wnt/β-catenin pathway-related proteins GSK3β, p-GSK3β, β-catenin and RUNX-2; (C) Quantification of the Western blotting. * Compared with the control group; # compared with CPS group.

Application: IHC    Species: Mice    Sample: bone and osteoid tissues

Fig. 9 (A) Masson staining: the region between surrounding bone and scaffold (40x & 100x); (B) TRAP staining: TRAP positive cells (black arrows); (C) IHC staining of RUNX-2; (D) IHC staining of ALP; (E) Quantitative analysis for TRAP staining and IHC staining. * Compared with CPS group; # compared with Sr-5 group.
3). Gene-Activating Framework Nucleic Acid-Targeted Upregulating Sirtuin-1 to Modulate Osteoimmune Microenvironment for Diabetic Osteoporosis Therapeutics. ACS nano, 2024 (PubMed: 39689347) [IF=15.8]
4). Gene-Activating Framework Nucleic Acid-Targeted Upregulating Sirtuin-1 to Modulate Osteoimmune Microenvironment for Diabetic Osteoporosis Therapeutics. ACS nano, 2024 (PubMed: 39689347) [IF=15.8]
5). Vascular Derived ECM Improves Therapeutic Index of BMP‐2 and Drives Vascularized Bone Regeneration. Small, 2022 (PubMed: 35218305) [IF=13.0]
6). Gold nanoparticles targeting the autophagy–lysosome system to combat the inflammation-compromised osteogenic potential of periodontal ligament stem cells: From mechanism to therapy. Biomaterials, 2022 (PubMed: 36030103) [IF=12.8]
7). Fusion peptide engineered “statically-versatile” titanium implant simultaneously enhancing anti-infection, vascularization and osseointegration. Biomaterials, 2021 (PubMed: 33069134) [IF=12.8]
8). Polydatin accelerates osteoporotic bone repair by inducing the osteogenesis-angiogenesis coupling of bone marrow mesenchymal stem cells via the PI3K/AKT/GSK-3β/β-catenin pathway. International journal of surgery (London, England), 2025 (PubMed: 39248296) [IF=12.5]
9). Polydatin accelerates osteoporotic bone repair by inducing the osteogenesis-angiogenesis coupling of bone marrow mesenchymal stem cells via the PI3K/AKT/GSK-3β/β-catenin pathway. International journal of surgery (London, England), 2024 (PubMed: 39248296) [IF=12.5]

Application: WB    Species: Rat    Sample:

Figure 1. POL stimulated BMSCs proliferation and osteogenic differentiation. (A) POL chemical structure; (B) BMSCs surface markers were detected by flow cytometry; (C) The result of CCK-8 assay (n = 5); (D-E) The result of CFU assay (n = 5); (F) Images of ALP staining (scale bar = 250 μm); (G) Quantification of ALP staining (n = 5); (H) Images of ARS staining (scale bar = 250 μm); (I) Quantification of ARS staining (n = 5); (J-K) The protein expression levels of OCN, RUNX2, ALP, and COL1A1 were evaluated by western blot (n = 3); (L-M) Immunofluorescence staining of OCN and ALP (scale bar = 200 μm). Data were presented as mean ± SEM. Compared with control group: * P < 0.05, **P < 0.01, ***P < 0.001. Compared with 1 μM group: # P < 0.05, ##P < 0.01, ###P < 0.001.
10). On-demand storage and release of antimicrobial peptides using Pandora's box-like nanotubes gated with a bacterial infection-responsive polymer. Theranostics, 2020 (PubMed: 31903109) [IF=12.4]

Application: WB    Species: Human    Sample: Human bone mesenchymal stem cells（hBMSCs）

Figure 5. In vitro biocompatibilities and osteogenic activities of the substrates. (A) CCK-8 assay of hBMSCs on the indicated surfaces after 1, 3 and 7 days of culture. * denotes p < 0.05 and ** denotes p < 0.01 compared to Ti-NTs, # denotes p < 0.05 compared to the corresponding control group without peptides. Error bars denote the standard deviations over quadruplicate measurements with separately implants. (B) Confocal fluorescence microscopy images of hBMSCs stained with vinculin, F-actin and DAPI after being cultured for 24 h. Scale bar, 50 μm. (C-F) qRT-PCR assay of osteogenic gene expression of (C) ALP, (D) RUNX-2, (E) COL1 and (F) OPN of hBMSCs after 7 and 14 days of culture. * denotes p < 0.05, ** denotes p < 0.01 and *** denotes p < 0.001 compared to Ti-NTs-P-A; # denotes p < 0.05, & denotes p < 0.01 and $ denotes p < 0.001 compared to the corresponding control group without peptides. All error bars denote the standard deviations over quadruplicate measurements with separately implants. (G) Immunofluorescence staining of hBMSCs cultured on Ti-NTs-P-A for 7 days (ALP and RUNX-2) and 14 days (OPN). The images were obtained by confocal fluorescence microscopy. Scale bar, 50 μm. (H) Western blotting of hBMSCs cultured on the substrates for 7 and 14 days. At each time point, left lane was Ti-NTs, middle lane was Ti-NTs-A and right lane was Ti-NTs-P-A. * denotes p < 0.05, ** denotes p < 0.01 and *** denotes p < 0.001 compared to Ti-NTs-P-A. Error bars denote the standard deviations over triplicate measurements with separately Western blotting results.
加载更多

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.